Skip to main content
Article thumbnail
Location of Repository

Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study

By Claudia Pena Rossi, Stephen B Hanauer, Ratko Tomasevic, John O Hunter, Ira Shafran and Hans Graffner
Topics: Research Article
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (1993). [Alpha-interferon therapy in Crohn's disease: initial clinical results]. Schweiz Med Wochenschr
    2. (2001). An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis.
    3. (2006). Daperno M: Advances in biologic therapy for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep
    4. (2007). DC: Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a. World J Gastroenterol
    5. (1980). De Somer P: Treatment of Crohn's disease with interferon. A preliminary clinical trial. Acta Clin Belg
    6. Declaration of Helsinki: Ethical principles for medical research involving human subjects [ icy/b3.htm]
    7. (2005). Engelberg Feurle G: Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol
    8. (1997). F: Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology
    9. (2008). Graffner H: Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-1a in moderately active ulcerative colitis. Aliment Pharmacol Ther
    10. Guidance for industry. E6 Good Clinical Practice: consolidated guidance []
    11. Hawkey CJ: European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 2006, 55(Suppl 1):i36-i58.
    12. (2007). Immune dysfunction in inflammatory bowel disease. Transl Res
    13. (2006). Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis
    14. (1998). Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology
    15. (1996). Inflammatory bowel disease: germs or genes? Lancet
    16. (2006). Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication.
    17. (1998). Interleukin-12 expression is focally enhanced in the gastric mucosa of pediatric patients with Crohn's disease.
    18. (2006). Lochs H: Conventional therapy for Crohn's disease.
    19. (1995). Lochs H: Prospective evaluation of interferon-alpha in treatment of chronic active Crohn's disease. Dig Dis Sci
    20. (1996). Meyer zum Buschenfelde KH, Strober W: Effect of IL-12 and antibodies to IL-12 on established granulomatous colitis in mice.
    21. (2006). Mortensen NJ: European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut
    22. (1998). Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis.
    23. Rebif® Prescribing Information
    24. (2006). Reinisch W: European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut
    25. (1997). Romagnani S: Type 1 Thelper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease.
    26. (2003). S: Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut
    27. (2008). S: New insights into inflammatory bowel disease pathophysiology: paving the way for novel therapeutic targets. Curr Drug Targets
    28. (2006). Shibasaki K: A case of exacerbation of ulcerative colitis induced by combination therapy with PEGinterferon alpha-2b and ribavirin. Gut
    29. (1999). SLF: Enhancing lamina propria Th1 cell responses with IL-12 produces severe tissue injury. Gasteroenterology
    30. (2007). Successful treatment of steroid refractory active ulcerative colitis with natural interferon-beta – an open long-term trial. Z Gastroenterol
    31. (1993). Tsujii T: Exacerbation of ulcerative colitis during alpha-interferon therapy for chronic hepatitis C. Intern Med
    32. (2006). Wynn DR: Management of Treatment Side Effects.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.